Advertisement

Insulin Resistance, Diabetes, and Cardiovascular Risk

  • Francesco Paneni
  • Sarah Costantino
  • Francesco CosentinoEmail author
Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Cardiovascular Disease and Stroke

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are major drivers of cardiovascular disease (CVD). The link between environmental factors, obesity, and dysglycemia indicates that progression to diabetes with time occurs along a “continuum”, not necessarily linear, which involves different cellular mechanisms including alterations of insulin signaling, changes in glucose transport, pancreatic beta cell dysfunction, as well as the deregulation of key genes involved in oxidative stress and inflammation. The present review critically addresses key pathophysiological aspects including (i) hyperglycemia and insulin resistance as predictors of CV outcome, (ii) molecular mechanisms underpinning the progression of diabetic vascular complications despite intensive glycemic control, and (iii) stratification of CV risk, with particular emphasis on emerging biomarkers. Taken together, these important aspects may contribute to the development of promising diagnostic approaches as well as mechanism-based therapeutic strategies to reduce CVD burden in obese and diabetic subjects.

Keywords

Insulin resistance Diabetes Cardiovascular disease 

Notes

Acknowledgments

Research discussed in this manuscript was supported by the Swiss Heart Foundation and the Italian Ministry of Education, University and Research, PRIN 2010-2011 (to F.C.). F.P was the recipient of a Ph.D. program in Experimental Medicine at the University of Rome “Sapienza”.

Compliance with Ethics Guidelines

Conflict of Interest

Francesco Paneni and Sarah Costantino declare that they have no conflicts of interest.

Francesco Cosentino reports grants from the Swiss Heart Foundation, the Italian Ministry of Education, University and Research, PRIN 2010-2011, personal fees from Roche, personal fees from Bristol Myers Squibb, personal fees from MSD, personal fees from Abbott, and personal fees from Astra Zeneca.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med. 2007;356:213–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96:1654–63.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126:1301–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Eckel RH. The complex metabolic mechanisms relating obesity to hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2011;31:1946–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Arsenault BJ, Beaumont EP, Despres JP, Larose E. Mapping body fat distribution: a key step towards the identification of the vulnerable patient? Ann Med. 2012;44:758–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Despres JP. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Investig. 2006;29:77–82.Google Scholar
  8. 8.
    Ryden L, Mellbin L. Joint ESC/EASD guidelines on diabetes, where are we now and where should we go? Curr Vasc Pharmacol. 2012;10:690–2.PubMedCrossRefGoogle Scholar
  9. 9.
    Paneni F. 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps. Diabetes Vasc Dis Res. 2014;11:5–10.CrossRefGoogle Scholar
  10. 10.
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34:2436–43.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013;34:2444–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Anselmino M, Ryden L. Strategies to enhance cardiovascular disease prevention in patients with diabetes. Curr Opin Cardiol. 2009;24:461–7.PubMedCrossRefGoogle Scholar
  15. 15.••
    Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–87. The recent ESC/EASD Guidelines on the management of diabetes and CVD represent an important document providing a systematic approach to diagnose and treat the combination of DM and CVD. The evidence-based strategy promoted by the ESC/EASD Guidelines will be invaluable for a consistent improvement of CV outcome in DM subjects, thus strengthening the importance of appropriate diagnostic and therapeutic algorithms to achieve the best care for patients in an individualized setting.PubMedCrossRefGoogle Scholar
  16. 16.
    Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980;1:1373–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W, et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006;27:2969–74.PubMedCrossRefGoogle Scholar
  18. 18.
    Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.PubMedCrossRefGoogle Scholar
  19. 19.
    The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–21.CrossRefGoogle Scholar
  20. 20.
    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Faerch K, Vaag A, Holst JJ, Hansen T, Jorgensen T, Borch-Johnsen K. Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care. 2009;32:439–44.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Kim SH, Reaven GM. Isolated impaired fasting glucose and peripheral insulin sensitivity: not a simple relationship. Diabetes Care. 2008;31:347–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE. 2012;7:e52036.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575–85.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Paneni F, Gregori M, Tocci G, Palano F, Ciavarella GM, Pignatelli G, et al. Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. Hypertens Res. 2013;36:36–42.PubMedCrossRefGoogle Scholar
  27. 27.
    Kumar R, Lee TT, Jeremias A, Ruisi CP, Sylvia B, Magallon J, et al. Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol. 2007;100:1187–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Uetani T, Amano T, Harada K, Kitagawa K, Kunimura A, Shimbo Y, et al. Impact of insulin resistance on post-procedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents. JACC Cardiovasc Interv. 2012;5:1159–67.PubMedCrossRefGoogle Scholar
  29. 29.
    Kim SH, Reaven GM. Insulin resistance and hyperinsulinemia: you can't have one without the other. Diabetes Care. 2008;31:1433–8.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25:1880–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Control G, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–98.CrossRefGoogle Scholar
  32. 32.
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.PubMedCrossRefGoogle Scholar
  34. 34.
    Cosentino F, Luscher TF. Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res. 1999;43:274–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.•
    Tabit CE, Shenouda SM, Holbrook M, Fetterman JL, Kiani S, Frame AA, et al. Protein kinase C-beta contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation. 2013;127:86–95. This study, performed in primary human endothelial cells isolated from T2DM patients, is the first to provide clear evidence concerning the activation of PKC-related pathways in the diabetic endothelium. These findings have important implications for mechanism-based therapeutic approaches to prevent vascular disease burden in diabetic patients.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106:1319–31.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Cosentino F, Francia P, Camici GG, Pelicci PG, Luscher TF, Volpe M. Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. Arterioscler Thromb Vasc Biol. 2008;28:622–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Paneni F, Cosentino F, Marrara F, Palano F, Capretti G, Gregori M, et al. The clinical relevance of dysfunctional HDL in patients with coronary artery disease: a 3-year follow-up study. Int J Cardiol. 2012;158:158–60.PubMedCrossRefGoogle Scholar
  40. 40.
    Migliaccio E, Giorgio M, Pelicci PG. Apoptosis and aging: role of p66Shc redox protein. Antioxid Redox Signal. 2006;8:600–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Trinei M, Migliaccio E, Bernardi P, Paolucci F, Pelicci P, Giorgio M. p66Shc, mitochondria, and the generation of reactive oxygen species. Methods Enzymol. 2013;528:99–110.PubMedCrossRefGoogle Scholar
  42. 42.
    Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A. 2007;104:5217–22.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Pagnin E, Fadini G, de Toni R, Tiengo A, Calo L, Avogaro A. Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. J Clin Endocrinol Metab. 2005;90:1130–6.PubMedCrossRefGoogle Scholar
  44. 44.•
    Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M, et al. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res. 2012;111:278–89. Our recent work provides mechanistic insights for the persistent of vascular dysfunction despite optimal glycemic control with insulin. We demonstrated that epigenetic changes of p66(Shc) promoter, namely DNA hypomethylation and increased histone 3 acetylation, drive persistent oxidative stress and endothelial dysfunction during subsequent normoglycemia. These data suggest that chromatin alterations may contribute to an explanation of the residual vascular risk in diabetic patients.Google Scholar
  45. 45.
    Paneni F, Volpe M, Luscher TF, Cosentino F. SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes. 2013;62:1800–7.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Ceriello A. The emerging challenge in diabetes: the “metabolic memory”. Vascu Pharmacol. 2012;57:133–8.CrossRefGoogle Scholar
  47. 47.
    El-Osta A. Glycemic memory. Curr Opin Lipidol. 2012;23:24–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res. 2010;107:1403–13.PubMedCrossRefGoogle Scholar
  49. 49.
    Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011;123:2145–56.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Paneni F, Costantino S, Volpe M, Luscher TF, Cosentino F. Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. Atherosclerosis. 2013;230:191–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349–54.PubMedCrossRefGoogle Scholar
  52. 52.••
    El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409–17. El-Osta et al. demonstrate for the first time that transient spikes of hyperglycemia activate persistent epigenetic signatures in the human endothelium leading to NF-kB upregulation and subsequent inflammation. This work indicates that glycemic flucutations rather than costant high glucose is a detrimental process triggering vascular damage in diabetic patients.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Picconi F, Di Flaviani A, Malandrucco I, Giordani I, Frontoni S. Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives. Nutr Metab Cardiovasc Dis. 2012;22:691–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Bazinet M, Hamdy S, Begin L, Aprikian A, Fair W, Wright G. Monoclonal-antibody pd-41 recognizes a prostate-cancer associated antigen whose expression increases in metastases and following hormonal-therapy. Int J Oncol. 1995;7:1421–5.PubMedGoogle Scholar
  55. 55.
    Bigornia SJ, Farb MG, Tiwari S, Karki S, Hamburg NM, Vita JA, et al. Insulin status and vascular responses to weight loss in obesity. J Am Coll Cardiol. 2013;62:2297–305.PubMedCrossRefGoogle Scholar
  56. 56.
    Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888–904.PubMedCrossRefGoogle Scholar
  57. 57.
    Kim JK. Endothelial nuclear factor kappaB in obesity and aging: is endothelial nuclear factor kappaB a master regulator of inflammation and insulin resistance? Circulation. 2012;125:1081–3.PubMedCrossRefGoogle Scholar
  58. 58.••
    Hasegawa Y, Saito T, Ogihara T, Ishigaki Y, Yamada T, Imai J, et al. Blockade of the nuclear factor-kappaB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation. 2012;125:1122–33. The article shows that the transcription factor NF-kB is critically involved in endothelial IR. Suppression of NF-kB signaling in the endothelium results in improved insulin signaling in other organs as well as improved lifespan in mice. These novel findings suggest that NF-kB is a key molecular intermediate linking metabolic disease, inflammation, and aging.PubMedCrossRefGoogle Scholar
  59. 59.
    Rask-Madsen C, Li Q, Freund B, Feather D, Abramov R, Wu IH, et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab. 2010;11:379–89.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest. 2006;116:1071–80.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab. 2011;13:294–307.PubMedCrossRefGoogle Scholar
  62. 62.
    Li Q, Park K, Li C, Rask-Madsen C, Mima A, Qi W, et al. Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-beta isoform in the endothelium. Circ Res. 2013;113:418–27.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005;258:250–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C, et al. Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin. Diabetes Vasc Dis Res. 2011;8:195–201.CrossRefGoogle Scholar
  65. 65.
    Avogaro A, de Kreutzenberg SV, Federici M, Fadini GP. The endothelium abridges insulin resistance to premature aging. J Am Heart Assoc. 2013;2:e000262.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006;27:713–21.PubMedCrossRefGoogle Scholar
  67. 67.
    Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J. 2011;32:2748–57.PubMedCrossRefGoogle Scholar
  68. 68.
    Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368–73.PubMedCrossRefGoogle Scholar
  69. 69.
    Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K, et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013;62:667–76.PubMedCrossRefGoogle Scholar
  70. 70.
    Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, D'Agostino Jr RB, et al. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab. 2010;95:2868–76.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Geisler T, Mueller K, Aichele S, Bigalke B, Stellos K, Htun P, et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol. 2010;99:743–52.PubMedCrossRefGoogle Scholar
  73. 73.
    Hohenstein B, Hugo CP, Hausknecht B, Boehmer KP, Riess RH, Schmieder RE. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant. 2008;23:1346–54.PubMedCrossRefGoogle Scholar
  74. 74.
    Meigs JB, Larson MG, Fox CS, Keaney Jr JF, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care. 2007;30:2529–35.PubMedCrossRefGoogle Scholar
  75. 75.
    Paneni F, Cosentino F. Advanced glycation endproducts and plaque instability: a link beyond diabetes. Eur Heart J. 2013. doi: 10.1093/eurheartj/eht454.PubMedCentralGoogle Scholar
  76. 76.
    Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324–30.PubMedCrossRefGoogle Scholar
  77. 77.
    Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res. 2012;93:583–93.PubMedCentralPubMedCrossRefGoogle Scholar
  78. 78.
    Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110:508–22.PubMedCrossRefGoogle Scholar
  79. 79.•
    Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810–7. This comprehensive analysis shows an array of deregulated miRs in diabetic patients, thus shedding some light on potential biomarkers in this arena. Among other miRs, miR-126, an important pro-angiogenic precursor, was significantly downregulated in plasma samples from T2DM patients.PubMedCrossRefGoogle Scholar
  80. 80.
    Mocharla P, Briand S, Giannotti G, Dorries C, Jakob P, Paneni F, et al. AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. Blood. 2013;121:226–36.PubMedCrossRefGoogle Scholar
  81. 81.
    Shantsila E, Kamphuisen PW, Lip GY. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost. 2010;8:2358–68.PubMedCrossRefGoogle Scholar
  82. 82.
    Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B, Aharon A. Involvement of microparticles in diabetic vascular complications. Thromb Haemost. 2011;106:310–21.PubMedCrossRefGoogle Scholar
  83. 83.
    Chen Y, Feng B, Li X, Ni Y, Luo Y. Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2012;14:455–60.CrossRefGoogle Scholar
  84. 84.
    Bernard S, Loffroy R, Serusclat A, Boussel L, Bonnefoy E, Thevenon C, et al. Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis. 2009;203:429–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Francesco Paneni
    • 1
  • Sarah Costantino
    • 1
  • Francesco Cosentino
    • 1
    Email author
  1. 1.Cardiology Unit, Department of MedicineKarolinska University Hospital, SolnaStockholmSweden

Personalised recommendations